유전체학 AI 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 컴포넌트별, 기술별, 기능별, 용도별, 최종 용도별, 지역별 경쟁(2021-2031년)

The Global AI in Genomics Market is projected to expand from USD 733.03 Million in 2025 to USD 1314.98 Million by 2031, registering a CAGR of 10.23%. This sector centers on the utilization of machine learning algorithms and computational intelligence to decode intricate genetic datasets, thereby fostering advancements in precision medicine, clinical diagnostics, and drug discovery. A primary growth engine is the substantial decrease in DNA sequencing costs coupled with the urgent demand for personalized healthcare solutions that necessitate the rapid analysis of biological data. According to the Global Alliance for Genomics and Health, in 2024, their partner network managed over 3,000,000 genomes, creating a massive volume of standardized data essential for training robust, high-performance models, which serves as a foundational pillar for the sector's accelerated development.

Nevertheless, a major challenge hindering broader market scalability is the strict regulatory environment regarding data privacy and ethical governance. The inherent sensitivity of genomic data demands rigorous adherence to international data protection frameworks, often resulting in informational silos that impede cross-border collaboration. These complex legal and ethical obstacles complicate the data sharing required for algorithmic validation, potentially delaying the commercialization and deployment of AI tools across diverse healthcare systems.

Market Driver

The imperative to accelerate drug discovery and development acts as a primary catalyst for market expansion, driven by the escalating costs and high failure rates associated with traditional pharmacological research. AI technologies are increasingly deployed to streamline target identification and validation, significantly reducing the time required to advance novel therapies to clinical trials. This trend is exemplified by substantial capital inflows into AI-native biotech firms, which confirm the commercial viability of these computational approaches. For instance, Xaira Therapeutics announced in April 2024 that it launched with $1 billion in committed capital to revolutionize drug development through generative AI models, underscoring the industry's pivot toward computational biology as a standard modality for creating effective medicines.

Simultaneously, rapid advancements in AI and machine learning capabilities are dismantling previous technical barriers, enabling the precise interpretation of multimodal genomic datasets. The emergence of generative AI and specialized microservices allows researchers to model complex biological interactions with unprecedented speed and fidelity, moving beyond simple sequence alignment to predictive functional genomics. In March 2024, NVIDIA introduced roughly 25 new generative AI microservices specifically designed to accelerate workflows in drug discovery and genomics. Furthermore, algorithmic sophistication is enhancing predictive precision; in May 2024, Google DeepMind reported that its AlphaFold 3 model demonstrated at least a 50% improvement in prediction accuracy for protein-ligand interactions compared to traditional methods, marking a fundamental leap for scaling genomic analysis in precision medicine applications.

Market Challenge

The stringent regulatory landscape surrounding data privacy and ethical governance constitutes a formidable barrier to the growth of the Global AI in Genomics Market. While AI algorithms require vast, diverse datasets to identify rare genetic correlations and validate precision medicine models, varying international data protection laws compel organizations to store information in isolated silos. This fragmentation prevents the cross-border data aggregation necessary for training universally applicable models, thereby limiting the diagnostic accuracy of AI tools across different demographics.

Furthermore, the complexity of adhering to these divergent frameworks increases operational costs and extends development timelines, effectively slowing the commercialization of genomic innovations. The fear of non-compliance and data misuse significantly stalls the adoption of these technologies among practitioners who are essential for market expansion. According to the American Medical Association, in 2024, 87% of physicians cited data privacy assurances as a critical requirement before they would integrate AI-driven tools into their clinical practices. This widespread reluctance, driven by regulatory complexities, directly delays the deployment of personalized healthcare solutions and restricts the market's scalability.

Market Trends

The emergence of Large Genomic Foundation Models marks a pivotal shift from task-specific algorithms to generalized architectures capable of interpreting the fundamental code of life across diverse biological domains. Unlike earlier models limited to narrow applications, these "DNA language models" utilize self-supervised learning on vast corpora of unannotated sequences to decipher complex evolutionary patterns and non-coding region functions without explicit labeling. This architectural advancement enables the generative design of novel genomic sequences with unprecedented predictive fidelity, facilitating breakthroughs in synthetic biology. According to the Arc Institute, in February 2025, the organization introduced its Evo 2 model, trained on 9.3 trillion DNA base pairs from over 128,000 genomes, achieving state-of-the-art accuracy in predicting mutation effects and designing synthetic biological systems.

Concurrently, the proliferation of AI-enhanced precision oncology tools is driving the rapid commercialization of clinical diagnostics, transitioning genomic analysis from research laboratories to routine patient care. AI-native diagnostic firms are scaling their operations by integrating multimodal clinical and molecular data, effectively bridging the gap between sequencing capabilities and actionable therapeutic insights. This surge in adoption demonstrates that healthcare providers are increasingly relying on computational intelligence to guide treatment decisions for complex cancer cases, validating the market's move toward scalable clinical utility. According to Tempus AI's August 2025 earnings report, the company's genomics revenue increased 115.3% year-over-year to $241.8 million, underscored by accelerating volume growth in its AI-enabled oncology testing portfolio.

Key Market Players

• IBM Corp.
• Deep Genomics Inc.
• Nvidia Corporation
• Data4Cure, Inc.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Sophia Genetics S.A.
• Freenome Holdings, Inc.
• BenevolentAI Ltd.
• Genentech, Inc.

Report Scope

In this report, the Global AI In Genomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

AI In Genomics Market, By Component

• Hardware
• Software
• Services

AI In Genomics Market, By Technology

• Machine Learning
• Computer Vision

AI In Genomics Market, By Functionality

• Genome Sequencing
• Gene Editing
• Others

AI In Genomics Market, By Application

• Drug Discovery & Development
• Precision Medicine
• Diagnostics
• Others

AI In Genomics Market, By End Use

• Pharmaceutical and Biotech Companies
• Healthcare Providers
• Research Centers
• Others

AI In Genomics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global AI In Genomics Market.

Available Customizations:

Global AI In Genomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global AI In Genomics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Hardware, Software, Services)
  • 5.2.2. By Technology (Machine Learning {Deep Learning, Supervised Learning, Unsupervised Learning, Others}, Computer Vision)
  • 5.2.3. By Functionality (Genome Sequencing, Gene Editing, Others)
  • 5.2.4. By Application (Drug Discovery & Development, Precision Medicine, Diagnostics, Others)
  • 5.2.5. By End Use (Pharmaceutical and Biotech Companies, Healthcare Providers, Research Centers, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America AI In Genomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Technology
  • 6.2.3. By Functionality
  • 6.2.4. By Application
  • 6.2.5. By End Use
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States AI In Genomics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Functionality
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End Use
  • 6.3.2. Canada AI In Genomics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Functionality
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End Use
  • 6.3.3. Mexico AI In Genomics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Functionality
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End Use

7. Europe AI In Genomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Technology
  • 7.2.3. By Functionality
  • 7.2.4. By Application
  • 7.2.5. By End Use
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany AI In Genomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Functionality
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End Use
  • 7.3.2. France AI In Genomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Functionality
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End Use
  • 7.3.3. United Kingdom AI In Genomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Functionality
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End Use
  • 7.3.4. Italy AI In Genomics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Functionality
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End Use
  • 7.3.5. Spain AI In Genomics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Functionality
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End Use

8. Asia Pacific AI In Genomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Technology
  • 8.2.3. By Functionality
  • 8.2.4. By Application
  • 8.2.5. By End Use
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China AI In Genomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Functionality
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End Use
  • 8.3.2. India AI In Genomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Functionality
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End Use
  • 8.3.3. Japan AI In Genomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Functionality
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End Use
  • 8.3.4. South Korea AI In Genomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Functionality
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End Use
  • 8.3.5. Australia AI In Genomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Functionality
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End Use

9. Middle East & Africa AI In Genomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Technology
  • 9.2.3. By Functionality
  • 9.2.4. By Application
  • 9.2.5. By End Use
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia AI In Genomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Functionality
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End Use
  • 9.3.2. UAE AI In Genomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Functionality
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End Use
  • 9.3.3. South Africa AI In Genomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Functionality
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End Use

10. South America AI In Genomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Technology
  • 10.2.3. By Functionality
  • 10.2.4. By Application
  • 10.2.5. By End Use
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil AI In Genomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Functionality
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End Use
  • 10.3.2. Colombia AI In Genomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Functionality
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End Use
  • 10.3.3. Argentina AI In Genomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Functionality
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global AI In Genomics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. IBM Corp.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Deep Genomics Inc.
• 15.3. Nvidia Corporation
• 15.4. Data4Cure, Inc.
• 15.5. Illumina, Inc.
• 15.6. Thermo Fisher Scientific Inc.
• 15.7. Sophia Genetics S.A.
• 15.8. Freenome Holdings, Inc.
• 15.9. BenevolentAI Ltd.
• 15.10. Genentech, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer